The Potential, Challenges and Solutions of Oncolytic Virotherapy
DOI:
https://doi.org/10.61173/dph08c88Keywords:
Oncolytic therapy, Limitations, Improve-ment strategiesAbstract
The traditional therapy of cancer has some limitations, for example the poor targeting, high toxicity, limited curative effect of the later period and so on. However, the oncolytic virus therapy can greatly kill the tumor cells. The OVs mainly use the direct dissolution of the tumor cells and the remodeling of TME to activate the antitumor activity to kill the tumor cells. The review generally finds out the oncolytic virus therapy still has three limitations. Firstly, The low targeting efficiency of OVs. Secondly, the inhibiting effect of TME on OVs. Thirdly, immune clearance and drug resistance. The review also finds three ways to help improve the curative effect of tumors such as Virus Modification, Regulating the tumor microenvironment and Immunological enhancement. The review thoroughly explores the killing mechanism of OVs, three present defects and three solutions. The exploration provides theoretical basis and thinkings for exploiting more curative oncolytic virus therapies in the future.
References
[1] Volovat, S. R., Scripcariu, D. V., Vasilache, I. A., Stolniceanu, C. R., Volovat, C., Augustin, I. G., Volovat, C. C., Ostafe, M. R., Andreea-Voichița, S. G., Bejusca-Vieriu, T., Lungulescu, C. V., Sur, D., & Boboc, D. (2024). Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. International journal of molecular sciences, 25(2), 1180.
[2] Jafari, M., Kadkhodazadeh, M., Shapourabadi, M. B., Goradel, N. H., Shokrgozar, M. A., Arashkia, A., Abdoli, S., & Sharifzadeh, Z. (2022). Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Frontiers in immunology, 13, 1012806.
[3] Kooti, W., Esmaeili Gouvarchin Ghaleh, H., Farzanehpour, M., Dorostkar, R., Jalali Kondori, B., & Bolandian, M. (2021). Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?. Frontiers in oncology, 11, 761015.
[4] Maroun, J., Muñoz-Alía, M., Ammayappan, A., Schulze, A., Peng, K. W., & Russell, S. (2017). Designing and building oncolytic viruses. Future virology, 12(4), 193–213. https://doi. org/10.2217/fvl-2016-0129
[5] Cao X. Medical Immunology[M]. 7th ed. Beijing: People’s Medical Publishing House, 2018.
[6] Aspirin, A. P., de Los Reyes V, A. A., & Kim, Y. (2021). Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment. Journal of the Royal Society, Interface, 18(174), 20200669.
[7] Xia, Y., Li, D., Yang, K., & Ou, X. (2025). Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy. International Journal of Molecular Sciences, 26(14), 6900.
[8] He, Y., Li, W., Zhang, X., & Cui, Z. (2025). Oncolytic virus targeted therapy for glioma via intravenous delivery. Advanced Healthcare Materials, 14(7), 2404965.
[9] Pierce Kyle M., Miklavcic William R., Cook Kyle P., Hennen Mikayla Sweitzer, Bayles Kenneth W., Hollingsworth Michael A., ... & Dailey Kaitlin M. (2021). The evolution and future of targeted cancer therapy: From nanoparticles, oncolytic viruses, and oncolytic bacteria to the treatment of solid tumors. Nanomaterials, 11(11), 3018.
[10] Hill, C., & Carlisle, R. (2019). Achieving systemic delivery of oncolytic viruses. Expert opinion on drug delivery, 16(6), 607-620.
[11] Shen, Z., Liu, X., Fan, G., Na, J., Liu, Q., Lin, F., Zhang, Z., & Zhong, L. (2023). Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages. Journal of translational medicine, 21(1), 842.
[12] Van Dalen, F. J., Van Stevendaal, M. H., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018). Molecular repolarisation of tumour-associated macrophages. Molecules, 24(1), 9.
[13] Gong, X., Ma, T., Zhang, Q., Wang, Y., Song, C., Lai, M., Zhang, C., Fang, X., & Chen, X. (2023). Porcine Reproductive Dean&Francis Xiyao Ling, Xiaotong Sun and Respiratory Syndrome Virus Modulates the Switch of Macrophage Polarization from M1 to M2 by Upregulating MoDC-Released sCD83. Viruses, 15(3), 773.
[14] Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., Kim, J. H., & Kim, C. (2019). Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(5), 1612–1623.
[15] Tang, G., Wang, D., Zhao, X., Feng, Z., Chen, Q., & Shen, Y. (2023). The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles. International Journal of Molecular Sciences, 24(4), 3681.
[16] Tian, Y., Xie, D., & Yang, L. (2022). Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy, 7(1), 117.
[17] Chouljenko, D. V., Murad, Y. M., Lee, I. F., Delwar, Z., Ding, J., Liu, G., ... & Jia, W. W. G. (2023). Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. Molecular Therapy-Oncolytics, 28, 334- 348.
[18] Chianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., ... & Franci, G. (2021). Oncolytic viruses in combination therapeutic approaches with epigenetic modulators: Past, present, and future perspectives. Cancers, 13(11), 2761.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
